Lone Henriksen comments

“Irritating and allergenic properties. We are very excited about these positive results as it follows our targets in preparation for the market launch of the product in H1 2021/2022.” These results confirm that Psoriasis lotion show positive effects and can be used as an adjunctive treatment product. It also proofs that the product can be categorized as non-irritation/ non allergenic.  

The application test

The product (Psoriasis lotion) was tested in the hypoallergenic program carried out at the Dermatology Clinic of the Medical University of Gdansk. The objective of the application test was to evaluate functional properties, effectiveness, and tolerance of the product marked 20003214 (Psoriasis lotion).

The sample consisted of 60 people of both sexes aged from 22 to 72 with various types of skin. The subjects were qualified for the sample based on personal medical examinations performed by a dermatologist-allergologist.

The positive test results are summarized as following:

For more detailed information on the results, see appendix A attached to this press release.
 

The dermatological test

The objective of the dermatological test was to evaluate irritating and allergenic properties of the product marked as: 20003214 (Psoriasis lotion). The test was  performed on the skin of adults with the use of a patch test.

The tests were carried out in two stages, on the group of 50 people of Caucasian race, with I-IV  Fitzpatrick (classification of the skin by its reaction to exposure to sunlight) skin types .

The first stage of the test took place at the „Kogotest” Dermatology Treatment Room in Gdansk which involved 19 women and 11 men aged from 20–70. The second stage of the test was performed at the Allergology Laboratory, Dermatology Clinic of the Medical University of Gdansk, with the participation of 20 patients (11 females; 9 men aged 19–57) with reported allergic dermatoses  

The positive test results are summarized as following

• Negative patch test results in patients who showed positive results of tests with standard allergens confirm that the product has no allergenic properties.

• Obtained test results cannot rule out individual hypersensitivity to the product in people with allergies to any of its ingredients.

For more detailed information on the results, see attached in appendix B in this press release.
 

For more information about CS MEDICA, please contact:

Lone Henriksen, CEO
Phone: + (45) 71 20 30 47
Email: lh@galaxapharma.com
Website: https://www.cs-medica.com/

CS MEDICA A/S is a Danish medico cannabis company founded in 2011. CS MEDICA is committed to developing, manufacturing, and commercializing over-the-counter (OTC) medical device products containing cannabinoids. The Company runs its business through the two fully-owned subsidiaries, Galaxa Pharma A/S (distributor and representative of foreign manufacturers in the Nordic, registered medical device product distributor) and CanNordic A/S (Medical device developer and seller (BtB), registered medical device product  manufacturer). CS MEDICA distributes products across the European borders and is headquartered in Copenhagen, Denmark.